Esculetin inhibits cell proliferation through the Ras/ERK1/2 pathway in human colon cancer cells

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 223-230

  Park, Sung Suk ^a   Park, Sung Kyu ^b   Lim, Jung Hyurk ^a   Choi, Yung Hyun ^c   Kim, Wun Jae ^d   Moon, Sung Kwon ^a,d  

^a Chungju National University   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Dong Eui University   (South Korea)

^d Chungbuk National University College of Medicine   (South Korea)

Author keywords

ERK1 2; Esculetin; HCT116 cells; P27KIP; Ras

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; ESCULETIN; MITOGEN ACTIVATED PROTEIN KINASE 1; RAS PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL PROLIFERATION; CELL SEPARATION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FLOW CYTOMETRY; GENES, RAS; HCT116 CELLS; HUMANS; IMMUNOPRECIPITATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RAS PROTEINS; TRANSFECTION; UMBELLIFERONES;

EID: 78650742213     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001064     Document Type: Article

References (39)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 259, 2005.
2. Arber N and Levin B: Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res 166: 213-230, 2005.
3. Campos FG, Logullo Waitzberg AG, Kiss DR, Waitzberg DL, Habr-Gama A and Gama-Rodrigues J: Diet and colorectal cancer: current evidence for etiology and prevention. Nutr Hosp 20: 18-25, 2005.
4. Kinzler KW and Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87: 159-170, 2006.
5. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, Leppert MF and Slattery ML: Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99: 597-602, 2002.
6. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M and Rougier P: CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283-1287, 1995.
7. Cvitkovic E and Bekradda M: Oxaliplatin: a new therapeutic option in colorectal cancer. Semin Oncol 26: 647-662, 1999. (Pubitemid 30013272)
8. Guichard S Cussac D, Hennebelle I, Bugat R and Canal P: Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT29 in vitro and in vivo. Int J Cancer 73: 729-734, 1997.
9. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE and Schmitz F: The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 32: 838-846, 2002.
10. Kaur M, Mandair R, Agarwal R and Agarwal C: Grape seed extract induces cell cycle arrest and apoptosis in human colon carcinoma cells. Nutr Cancer 60 (Suppl 1): 2-11, 2008.
11. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
12. Peter M and Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79: 181-184, 1994.
13. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79: 551-555, 1994.
14. Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268: 14553-14556, 1993.
15. Karin M and Hunter T: Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 5: 747-757, 1995.
16. Cobb M and Goldsmith EJ: How MAP kinases are regulated. J Biol Chem 270: 14843-14846, 1995.
17. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
18. Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH and Yancopoulos GD: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65: 663-675, 1991.
19. Segal R and Greenberg M: Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci 19: 463-489, 1996.
20. Rundén E, Seglen PO, Haug FM, Ottersen OP, Wieloch T, Shamloo M and Laake JH: Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinasedependent mechanism. J Neurosci 18: 7296-7305, 1998.
21. Lee ER, Kang YJ, Kim JH, Lee HT and Cho SG: Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem 280: 31498-31507, 2005.
22. Park JI, Strock CJ, Ball DW and Nelkin BD. The Ras/Raf/ MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol 23: 543-554, 2003.
23. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
24. Chambard JC, Lefloch R, Pouyssegur J and Lenormand P: ERK implication in cell cycle regulation. Biochim Biophys Acta 1773: 1299-1310, 2007.
25. Fanton CP, McMahon M and Pieper RO: Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem 276: 18871-18877, 2001.
26. Malumbres M, Pérez De Castro I, Hernγndez MI, Jiménez M, Corral T and Pellicer A: Cellular response to oncogenic ras involves induction of the Cdk4 and Cdk6 inhibitor p15(INK4b). Mol Cell Biol 20: 2915-2925, 2000.
27. Sekiya K, Okuda H and Arichi S: Selective inhibition of platelet lipoxygenase by esculetin. Biochim Biophys Acta 713: 68-72, 1982. (Pubitemid 13206455)
28. Lin WL, Wang CJ, Tsai YY, Liu CL, Hwang JM and Tseng TH: Inhibitory effect of esculetin on oxidative damage induced by tbutyl hydroperoxide in rat liver. Arch Toxicol 74: 467-472, 2000.
29. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E and Thornes RD: The pharmacology, metabolism, analysis and applications of coumarin and coumarin-related compounds. Drug Metab Rev 22: 503-529, 1990.
30. Okada Y, Miyauchi Y, Suzuki K and Kobayashi T: Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. Chem Pharm Bull 43: 1385-1387, 1995.
31. Wang CJ, Hsieh YJ, Chu CY, Lin YL and Tseng TH: Inhibition of cell cycle progression in human leukemia HL-60 cells by esculetin. Cancer Lett 183: 163-168, 2002.
32. Pan SL, Huang YW, Guh JH, Chang YL, Peng CY and Teng CM: Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats. Biochem Pharmacol 65: 1897-1905, 2003.
33. Huang HC, Lai MW, Wang HR, Chung YL, Hsieh LM and Chen CC: Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways. Eur J Pharmacol 237: 39-44, 1993.
34. Kaneko T, Tahara S and Takabayashi F: Inhibitory effect of natural coumarin compounds, esculetin and esculin, on oxidative DNA damage and formation of aberrant crypt foci and tumors induced by 1,2-dimethylhydrazine in rat colons. Biol Pharm Bull 30: 2052-2057, 2007.
35. Moon SK, Jung SY, Choi YH, Lee YC, Patterson C and Kim CH: PDTC, metal chelating compound, induces G1 phase cell cycle arrest in vascular smooth muscle cells through inducing p21Cip1 expression: involvement of p38 mitogen activated protein kinase. J Cell Physiol 198: 310-323, 2004.
36. Moon SK, Kim HM, Lee YC and Kim CH: Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression. J Biol Chem 279: 33063-33070, 2004.
37. Kok SH, Yeh CC, Chen ML and Kuo MY: Esculetin enhances TRAIL-induced apoptosis through DR5 upregulation in human oral cancer SAS cells. Oral Oncol 45: 1067-1072, 2009.
38. Lee SH, Park C, Jin CY, Kim GY, Moon SK, Hyun JW, Lee WH, Choi BT, Kwon TK, Yoo YH and Choi YH: Involvement of extracellular signal-related kinase signaling in esculetin induced G1 arrest of human leukemia U937 cells. Biomed Pharmacother 62: 723-729, 2008.
39. Park C, Jin CY, Kim GY, Choi IW, Kwon TK, Choi BT, Lee SJ, Lee WH and Choi YH: Induction of apoptosis by esculetin in human leukemia U937 cells through activation of JNK and ERK. Toxicol Appl Pharmacol 227: 219-228, 2008.